跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 60 条关于
“PAXG”
全部
60
临床试验
39
药物
8
机构
1
资讯
12
10个月前
CASSANDRA Phase 3 Trial Shows PAXG Superior to mFOLFIRINOX in Preoperative Pancreatic Cancer Treatment
9个月前
PAXG Chemotherapy Shows Superior Event-Free Survival Over mFOLFIRINOX in Pancreatic Cancer Trial
去年
Meta-Analysis Identifies Optimal First-Line Chemotherapy Regimens for Advanced Pancreatic Cancer
去年
Ignite Biomedical's AI-Driven TNFi Treatment Response Predictor Achieves Analytical Validation
去年
QIAGEN Partners with Foresight Diagnostics and Tracer Biotechnologies to Expand Minimal Residual Disease Testing Portfolio
9个月前
FoRx Therapeutics Secures $50M Series A to Advance PARG Inhibitor for PARP-Resistant Cancers
去年
858 Therapeutics Secures $50 Million in Series B Funding to Advance PARG Inhibitor ETX-19477
去年
FoRx Therapeutics Doses First Patient with Novel PARG Inhibitor FORX-428 in Phase 1 Cancer Trial
8个月前
858 Therapeutics Receives FDA Fast Track Designation for PARG Inhibitor ETX-19477 in BRCA-Mutated Ovarian Cancer
7个月前
FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer, First New Treatment in Nearly 30 Years
第 1 页,共 2 页
上一页
下一页